{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:42:40Z","timestamp":1771047760143,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00984-4","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T09:01:31Z","timestamp":1691226091000},"page":"793-800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"984_CR1","unstructured":"US National Cancer Institute. Cancer stat facts: prostate cancer. 2023. https:\/\/seer.cancer.gov\/. Accessed 10 Jul 2023."},{"key":"984_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","volume":"157","author":"T Dyba","year":"2021","unstructured":"Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"984_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clgc.2017.08.006","volume":"16","author":"A Finianos","year":"2018","unstructured":"Finianos A, Gupta K, Clark B, et al. Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease. Clin Genitourin Cancer. 2018;16(1):85\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"984_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11934-015-0488-8","volume":"16","author":"B Bernard","year":"2015","unstructured":"Bernard B, Sweeney CJ. Management of metastatic hormone-sensitive prostate cancer. Curr Urol Rep. 2015;16(3):14.","journal-title":"Curr Urol Rep"},{"issue":"2","key":"984_CR5","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023;41(2):3595\u2013607.","journal-title":"J Clin Oncol"},{"key":"984_CR6","unstructured":"National comprehensive cancer network. NCCN clinical practice guidelines in oncology: prostate cancer - version 1.2023. 2022. https:\/\/www.nccn.org\/. Accessed 10 Jul 2023."},{"issue":"12","key":"984_CR7","first-page":"E581","volume":"16","author":"AI So","year":"2022","unstructured":"So AI, Chi K, Danielson B, et al. Update: Canadian urological association-Canadian urologic oncology group guideline: metastatic castration-naive and castration-sensitive prostate cancer. Can Urol Assoc J. 2022;16(12):E581\u20139.","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"984_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334.","journal-title":"Ann Oncol"},{"issue":"6","key":"984_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S, Committee EG. Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34(6):557\u201363.","journal-title":"Ann Oncol"},{"key":"984_CR10","unstructured":"European Association of Urology. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2023. https:\/\/uroweb.org\/. Accessed 10 Jul 2023."},{"key":"984_CR11","unstructured":"Bayer HealthCare Pharmaceuticals Inc. NUBEQA (darolutamide): US prescribing information. 2022. https:\/\/dailymed.nlm.nih.gov\/. Accessed 10 Jul 2023."},{"key":"984_CR12","unstructured":"European Medicines Agency. NUBEQA (darolutamide): EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/. Accessed 10 Jul 2023."},{"key":"984_CR13","unstructured":"Bayer Inc. NUBEQA (darolutamide): Japanese prescribing information [Japanese]. 2023. https:\/\/www.pmda.go.jp\/. Accessed 10 Jul 2023."},{"key":"984_CR14","unstructured":"Bayer Inc. Nubeqa\u2122 (darolutamide) approved for additional prostate cancer indication in China [media release]. 20 Mar 2023."},{"issue":"6","key":"984_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11523-020-00779-x","volume":"15","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Darolutamide: a review in non-metastatic castration-resistant prostate cancer. Target Oncol. 2020;15(6):791\u20139.","journal-title":"Target Oncol"},{"issue":"12","key":"984_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"984_CR17","doi-asserted-by":"publisher","first-page":"S1162","DOI":"10.1016\/j.annonc.2022.07.1492","volume":"33","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Smith M, Hussain M, et al. Quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study [abstract no. 1360MO]. Ann Oncol. 2022;33(Suppl 7):S1162.","journal-title":"Ann Oncol"},{"key":"984_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.955925","volume":"13","author":"T Jian","year":"2022","unstructured":"Jian T, Zhan Y, Hu K, et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Front Pharmacol. 2022;13: 955925.","journal-title":"Front Pharmacol"},{"issue":"6","key":"984_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605\u201316.","journal-title":"Eur Urol Oncol."},{"issue":"1","key":"984_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","volume":"9","author":"P Mandel","year":"2023","unstructured":"Mandel P, Hoeh B, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus. 2023;9(1):96\u2013105.","journal-title":"Eur Urol Focus"},{"key":"984_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.03.024","author":"B Hoeh","year":"2023","unstructured":"Hoeh B, Garcia CC, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume. Eur Urol Focus. 2023. https:\/\/doi.org\/10.1016\/j.euf.2023.03.024.","journal-title":"Eur Urol Focus"},{"key":"984_CR22","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.","journal-title":"Sci Rep"},{"issue":"4","key":"984_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-021-01078-y","volume":"61","author":"C Zurth","year":"2022","unstructured":"Zurth C, Nyk\u00e4nen P, Wilkinson G, et al. Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment. Clin Pharmacokinet. 2022;61(4):565\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"16 Suppl","key":"984_CR24","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1200\/JCO.2022.40.16_suppl.5078","volume":"40","author":"F Saad","year":"2022","unstructured":"Saad F, Hussain MHA, Tombal BF, et al. Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial [abstract no. 5078]. J Clin Oncol. 2022;40(16 Suppl):5078.","journal-title":"J Clin Oncol"},{"issue":"3","key":"984_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SCR Williams","year":"2023","unstructured":"Williams SCR, Mazibuko N, O\u2019Daly O, et al. Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial. Target Oncol. 2023;18(3):403\u201313.","journal-title":"Target Oncol"}],"updated-by":[{"DOI":"10.1007\/s11523-023-01003-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00984-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:17:44Z","timestamp":1695460664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00984-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-023-01003-2","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"10 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-023-01003-2","URL":"https:\/\/doi.org\/10.1007\/s11523-023-01003-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}